Pazopanib in Second-line Therapy in Renal Cell Carcinoma
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The principal aim of the study is to determine the objective response rate that offers the
second-line treatment with pazopanib in patients with carcinoma of advanced renal cells that
have progressed or that have not tolerated the first line of treatment with a Tyrosine Kinase
Inhibitor. The secondary aims are to determine the overall survival and the treatment safety
profile for these patients in second-line treatment with pazopanib. The exploratory aim is to
determine the correlation between biomarkers in patient blood and tumor samples, and the
clinical results obtained with pazopanib.